Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.40 |
| ▸ | FEN1 | P39748 | 2/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.35 |
| ▸ | PLA2G7 | Q13093 | 4/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29769062 | 1.00 | LOXL2 (0.42) | LOXL2LOXALOX5APFEN1RIPK2 | |
| SCHEMBL30753333 | 0.91 | LOXL2 (0.38) | LOXL2LOXALOX5APFEN1RIPK2 | |
| SCHEMBL24998894 | 0.89 | LOXL2 (0.40) | LOXL2LOXALOX5APFEN1RIPK2 | |
| SCHEMBL29769056 | 0.89 | LOXL2 (0.40) | LOXL2LOXALOX5APFEN1RIPK2 | |
| SCHEMBL21098839 | 0.89 | GCK (0.38) | LOXL2ALOX5APFEN1RIPK2KDR | |
| SCHEMBL19124891 | 0.86 | LOXL2 (0.42) | LOXL2LOXALOX5APFEN1RIPK2 | |
| SCHEMBL30997488 | 0.86 | LOXL2 (0.42) | LOXL2LOXALOX5APFEN1RIPK2 | |
| SCHEMBL30753296 | 0.85 | KDR (0.33) | ALOX5APFEN1RIPK2KDRGCK | |
| SCHEMBL23193922 | 0.84 | PLA2G7 (0.40) | LOXL2LOXALOX5APFEN1RIPK2 | |
| SCHEMBL14662000 | 0.84 | KDR (0.46) | LOXL2LOXALOX5APFEN1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748841-A1 | BICYCLO[5,6] IMIDAZOLE PYRIMIDONE DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shujing Biopharma Co., Ltd (CN) | 2026-05-27 | — | — | EP | disclosed |
| US-20250154153-A1 | DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF | 4B TECHNOLOGIES (BEIJING) CO., LIMITED (CN) | 2025-05-15 | — | — | US | disclosed |
| WO-2025015951-A1 | BICYCLO[5,6] IMIDAZOLE PYRIMIDONE DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海枢境生物科技有限公司 | 2025-01-23 | — | — | WO | disclosed |
| US-20240300965-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-12 | — | — | US | disclosed |
| CN-118221687-A | Bicyclo [5,6] imidazole pyrimidinone derivative, preparation method and application thereof | 上海枢境生物科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-11999746-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-06-04 | — | — | US | disclosed |
| US-20230357268-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | NEUSCO BIOTECH LIMITED (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357268-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | NEUSCO BIOTECH LIMITED (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230271980-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | NEUSCO BIOTECH LIMITED (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271980-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | NEUSCO BIOTECH LIMITED (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-2948456-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2015-12-02 | — | — | EP | disclosed |
| US-9051325-B2 | Bicyclic [5,6] imidazo pyrimodone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-06-09 | — | — | US | disclosed |
| US-9051325-B2 | Bicyclic [5,6] imidazo pyrimodone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-06-09 | — | — | US | disclosed |
| US-9051325-B2 | Bicyclic [5,6] imidazo pyrimodone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-06-09 | — | — | US | disclosed |
| WO-2014114249-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014114249-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014114694-A1 | 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-31 | — | — | WO | disclosed |
| US-20140213599-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-31 | — | — | US | disclosed |
| US-20140213599-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-31 | — | — | US | disclosed |
| WO-2014114694-A1 | 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213599-A1 | COMPOUNDS | LPCAT1, PLA2G7, PLAAT2 | LOXL2 147/4885LOX 118/4885ALOX5AP 37/4885 |
| US-20250154153-A1 | DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF | PLA2G4A, PLA2G1B, PLA2G4B | LOXL2 199/4885LOX 159/4885ALOX5AP 63/4885 |
| US-20240300965-A1 | COMPOUNDS | PLAAT2, PLA2G12A, PLA2G1B | LOXL2 210/4885LOX 151/4885ALOX5AP 40/4885 |
| US-11999746-B2 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | LOXL2 210/4885LOX 151/4885ALOX5AP 40/4885 |
| US-20230271980-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | PLA2G1B, PLA2G4B, PLA2G4A | LOXL2 195/4885LOX 146/4885ALOX5AP 60/4885 |
| US-20230357268-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | PLA2G1B, PLA2G4B, PLA2G5 | LOXL2 241/4885LOX 193/4885ALOX5AP 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.